Compare TIPT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIPT | OCS |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.9M | 732.4M |
| IPO Year | 2017 | 2022 |
| Metric | TIPT | OCS |
|---|---|---|
| Price | $17.33 | $7.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $36.73 |
| AVG Volume (30 Days) | 226.7K | ★ 272.4K |
| Earning Date | 10-30-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $488,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $365.20 |
| P/E Ratio | $51.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.49 | $7.85 |
| 52 Week High | $19.33 | $34.48 |
| Indicator | TIPT | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 21.73 |
| Support Level | $17.36 | N/A |
| Resistance Level | $17.56 | $13.49 |
| Average True Range (ATR) | 0.33 | 0.47 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 77.99 | 11.81 |
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.